QRG Capital Management Inc. Grows Holdings in Sanofi (NASDAQ:SNY)

QRG Capital Management Inc. boosted its position in Sanofi (NASDAQ:SNY - Free Report) by 8.7% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 152,406 shares of the company's stock after acquiring an additional 12,245 shares during the period. QRG Capital Management Inc.'s holdings in Sanofi were worth $8,783,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Manning & Napier Advisors LLC bought a new position in Sanofi in the 2nd quarter worth about $13,725,000. Mount Yale Investment Advisors LLC increased its holdings in Sanofi by 44.3% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company's stock worth $2,027,000 after acquiring an additional 12,806 shares during the period. Jennison Associates LLC boosted its holdings in Sanofi by 18.9% in the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company's stock valued at $9,216,000 after purchasing an additional 30,115 shares during the period. Sei Investments Co. boosted its holdings in Sanofi by 9.3% in the 1st quarter. Sei Investments Co. now owns 554,028 shares of the company's stock valued at $26,926,000 after purchasing an additional 47,297 shares during the period. Finally, Atria Investments Inc grew its holdings in shares of Sanofi by 31.1% during the first quarter. Atria Investments Inc now owns 98,878 shares of the company's stock worth $4,805,000 after purchasing an additional 23,463 shares in the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

SNY stock traded down $0.10 on Tuesday, hitting $52.85. The company had a trading volume of 851,806 shares, compared to its average volume of 2,026,889. The stock has a market cap of $134.12 billion, a price-to-earnings ratio of 26.96, a P/E/G ratio of 1.36 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock's 50-day simple moving average is $55.85 and its 200 day simple moving average is $52.10. Sanofi has a 12-month low of $45.00 and a 12-month high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the previous year, the company posted $2.55 earnings per share. Sanofi's revenue was up 12.3% compared to the same quarter last year. As a group, equities research analysts expect that Sanofi will post 4.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on SNY shares. StockNews.com upgraded shares of Sanofi from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, October 30th. Argus lifted their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, July 26th. Finally, Citigroup raised Sanofi to a "strong-buy" rating in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.